We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ayala Pharmaceuticals Inc (QX) | USOTC:ADXS | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.005 | -0.90% | 0.55 | 0.5305 | 0.625 | 0.55 | 0.5305 | 0.55 | 896 | 19:50:33 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 25, 2017
ADVAXIS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware |
001-36138
|
02-0563870
|
||
(State or Other Jurisdiction of Incorporation) |
(Commission
|
(IRS
Employer
Identification No.) |
305 College Road East
Princeton, New Jersey, 08540
(Address of Principal Executive Offices)
(609) 452-9813
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act. |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
[ ] | Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act. |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act [ ]
Item 8.01. Other Events.
Attached hereto as Exhibit 99.1 and incorporated herein by reference is a PowerPoint presentation, including a corporate overview of Advaxis, Inc., which will be made available on its website at www.advaxis.com.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
The following exhibit is filed as part of this report:
Exhibit
Number |
Description | |
99.1 | Company PowerPoint presentation. |
- 2 - |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Advaxis, Inc. | ||
(Registrant) | ||
Date: September 25, 2017 | ||
By: | /s/ Sara Bonstein | |
Sara Bonstein | ||
Executive
Vice President and
Chief Financial Officer |
- 3 - |
INDEX TO EXHIBITS
Exhibit
Number |
Description | |
99.1 | Company PowerPoint presentation. |
- 4 - |
1 Year Ayala Pharmaceuticals (QX) Chart |
1 Month Ayala Pharmaceuticals (QX) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions